BioCryst wins key Japanese government approval

 In Daily Digest

Share this story:

 Durham-based BioCryst Pharmaceuticals pharmaceutical is set to receive a $15 million payment from its Japanese partner after receiving approval for an oral drug intended to treat a swelling disorder. The  Japanese National Health Insurance System approved the addition of the company’s Orladeyo to its price list.  Torii Pharmaceutical of Japan partnered with BioCryst in November 2019 in a $44 million deal.

Recent Posts
Contact Us

Questions or feedback? Drop us a message!

Start typing and press Enter to search